The Hub for Disease-Specific Clinical Information
Advertisement
Advertisement

Wells A. Messersmith, MD, on Advanced Colorectal Cancer: Use of Molecular Biomarkers

Posted: Monday, April 1, 2019

Wells A. Messersmith, MD, of the University of Colorado Cancer Center, discusses what the updated NCCN Guidelines have to say about the use of molecular biomarkers in managing patients with advanced colorectal cancer as well as the ramifications of use (increased cost and time to obtain results).



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.